[A19-54] Nivolumab (renal cell carcinoma) - Addendum to Commissions A19-11 and A19-12
Last updated 15.08.2019
Project no.:
A19-54
Commission:
Commission awarded on 24.06.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Treatment-naive adults with intermediate or poor-risk advanced renal cell carcinoma
Result of dossier assessment:
Conclusion of dossier assessments A19-11 and A19-12 unchanged
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A19-12 | Ipilimumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A19-11 | Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2019-08-15 A G-BA decision was published.